South Korean biotech shares in turnaround mode Companies in the IPO pipeline find it difficult to set prices
Translated by Kim So-in 공개 2019-10-28 08:00:00
이 기사는 2019년 10월 28일 08:00 thebell 에 표출된 기사입니다.
South Korean biotechnology companies that lost almost half the value in the second half of the year are beginning to gain ground while worries on sudden turnaround linger in the stock market.The country's biotechnology shares have been on a roller-coaster over the last few months. Some shares have surged almost ten times since August.
The turnaround was led by HLB. After announcing its top-line results in June, HLB's shares plummeted to 20 thousand won in August. However the company's stocks have been rallying with HLB reaffirming the successful trial result and the company's likely pre-new drug application meeting with U.S. Food and Drug Administration on October 24. The Kosdaq-listed HLB's shares exceeded 180 thousand won and the market capitalization which was under one trillion won increased to seven trillion won. Now HLB is threatening to unseat Celltrion, the largest company on Kosdaq by market capitalization.
Shares of other biotechnology companies that are conducting phase three clinical trials such as SillaJen and Helixmith also have recovered ground.
The recent share price movement of companies conducting phase three clinical trials are affecting biotechnology firms on the Kosdaq market. Valuations of biotechnology companies, which have suffered in the second half of the year, are rising again. In addition, the fact that shares of U.S.-based Biogen soared also boosted domestic biotechnology stocks. Biogen recently surprised investors by saying its Alzheimer's treatment was ready to start the regulatory approval process.
On the other hand, South Korean biotechnology companies that are in the initial public offering (IPO) pipeline by the end of the year feel uncomfortable with current movement. Jetema and TiumBio submitted securities registration statements and book-building process is around the corner. Medpacto and NovMetaPharma passed preliminary examination and are adjusting the registration statement submission date.
Those companies all haven't set the IPO price yet. "As share prices of listed biotechnology companies rose rapidly, it becomes hard to set a price range. It would be easier to proceed with the listing procedure if the share prices were still low," said an unlisted biotechnology company official.
When stock valuations rocket, investor expect IPO prices to be lower to avoid risks of post-IPO falling stock price. Especially for companies who plan to submit securities registration statements, it is critical to value themselves appropriately amid rising share prices. If the companies set the price too high, they might fail to attract investor interests at the subscription process.
Experts expect Jetema and TiumBio's subscription results will likely serve as a litmus test for forthcoming IPOs. Both companies expect market capitalization of approximately 470 billion won at their listings. Jetema will conduct book-building process on October 30 and 31, while TiumBio will conduct it on November 5 and 6.
(By reporter Min Kyung-moon)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- 클로잇, 에어프레미아 클라우드 ERP 시스템 구축
- 저스템, JFS 수주 탄력받나…해외도 '관심집중'
- FSN 계열 대다모닷컴, '대다모 댄디' 서비스 론칭
- 브이티, 1분기 영업익 240억 달성
- [방산기업 국산화율 톺아보기]'K2' 산실 SNT모티브, 기관총으로 수출 정조준
- [중견화학사는 지금]6년 뒤 '주가 50만원' 목표하는 대한유화, 관건은 신사업
- [중견화학사는 지금]TKG휴켐스 이사회, 경영진 견제 미흡…지배구조 등급 'B'
- [Peer Match Up/광고 3사]글로벌·디지털 '인오가닉' 이후, 새판짜는 성장 전략
- [문화 산책]미술계 지금 주목할 전시들
- [2금융권 연체 리스크]하나캐피탈, 부동산PF·가계대출 총량 관리 '결실'